Duloxetine hydrochloride (DLX) is a serotonin and noradrenalin reuptake inhibitor mostly used for the treatment of major depressive and anxiety disorders. Physicochemical characterization of this drug and compatibility studies with excipients are particularly important during pharmaceutical technology development in order to guarantee the quality, safe and effective dosage form. Duloxetine is acid labile, thus the final product must be formulated with enteric coating to prevent degradation in the stomach for proper drug delivery. The major purpose of this work was to characterize this drug in solid-state form through thermal analytical techniques (TG/DTG, DSC), diffuse reflectance infrared Fourier transform (DRIFT) spectrophotometry, morphological analysis by scanning electron microscopy (SEM) and x-ray diffraction (XRD) analysis. The compatibility studies with excipients (1:1 w/w) was carried out using sodium starch glycolate (SSG), lactose (LAC), magnesium stearate (MS), croscarmellose sodium (CS), colloidal silicon dioxide (CSD) and microcrystalline cellulose (MCC). For DLX, the DSC analysis showed a sharp endothermic peak corresponding to the melting process (Tpeak = 168.93°C) and purity determination of 98.74 ± 0.03%. Thermogravimetry (TG) curves revealed a mass loss of approximately 58% during thermal decomposition and the non-isothermal kinetics revealed estimated Ea of 62.73 kJ mol-1 with a reaction order of zero, indicating that DLX thermal decomposition is constant over time, regardless of its concentration. The compatibility results suggest an interaction between DLX and selected excipients (SSG, CS, CSD, MCC) evidenced by the DLX melting point dislocation on the DSC curves.
Similar content being viewed by others
References
Depression and Other Common Mental Disorders: Global Health Estimates, WHO (2017). http://www.who.int/mental_health/management/depression/prevalence_global_health_ estimates/en/.Accessed 15 Apr 2018.
R. DeLucia, R. M. Oliveira-Filho, C. S. Planeta, et al., Farmacologia integrada, 3rd ed., Revinter, Rio de Janeiro (2007).
C. Mencacci, E. Aguglia, G. Biggio, et al., Clinicoecon Outcomes Res., 5, 611 – 621 (2013).
M. Lesley, L. M. Arnold, Pain Med., 8(2), S63-S74 (2007).
A. Darowski, S. C. F. Chambers, D. J. Chambers, Drugs Aging, 26(5), 381 – 394 (2009).
P. Srinivasulu, K. S. V. Srinivas, R. S. Reddy, et al., Pharmazie, 64, 10 – 13 (2009).
T. J. Moore, D. R. Mattison, JAMA Intern Med., 177(2), 274 – 275 (2017).
V. R. Sinha, Anamika, R. Kumria, et al., J. Chromatogr. Sci., 47, 589 – 593 (2009).
M. P. Knadler, E. Lobo, J. Chappell, and R. Bergstrom, Clin Pharmacokinet., 50(5), 281 – 294 (2011).
P. Patel, K. Ahir, V. Patel, et al., Pharma Innov. J., 4(5), 14 – 20 (2015).
D. Giron, Pharm. Sci. Technolo. Today, 1(5), 191 – 199 (1998).
R. Chadha and S. Bhandari, J. Pharm. Biomed. Anal., 87, 82 – 97 (2014).
T. Ding, L. Chen, L. H. Zhai, et al., J. Therm. Anal. Calorim., 130(3), 1569 – 1573 (2017).
I. Ledeti, S. Bolintineanu, G. Vlase, et al., J. Therm. Anal. Calorim., 130(1), 433 – 441 (2017).
A. Veiga, P. R. Oliveira, L. S. Bernardi, et al., J. Therm Anal Calorim., 131(3), 3201 – 3209 (2017).
L. J. Oliveira, N. C. F. Stofella, A. Veiga, et al., J. Therm Anal Calorim., 133(3), 1521 – 1533 (2018).
United States Pharmacopeia and National Formulary, USP 38-NF 33, Rockville, United States Pharmacopeia Convention (2015).
T. Ozawa, Bull. Chem. Soc., 38, 1881 – 1886 (1965).
J. H. Flynn and L. A. Wall, J. Res. Natl. Bur. Stand. A: Phys. Chem., 70A(6), 487 – 523 (1966).
F. S. Murakami, L. S. Bernardi, R. N. Pereira, et al., Pharm. Chem. J., 43(12), 716 – 720 (2009).
B. Tiþa, A. Fulia°, G. Bandur, et al., J. Pharm. Biomed. Anal., 56, 221 – 227 (2011).
M. Douša, P. Gibala, J. Havlíèek, et al., J. Pharm. Biomed. Anal., 55 5), 949 – 956 (2011).
L. A. D. Silva, F. V. Teixeira, R. C. Serpa, et al., J. Therm. Anal. Calorim., 123(3), 2337 – 2344 (2016).
M. S. Cunha-Filho, R. Martínez-Pacheco, and M. Landín, J. Pharm. Biomed. Anal., 45(4), 590 – 598 (2007).
K. Liltorp, T. G. Larsen, B.Willumsen, et al., J. Pharm. Biomed. Anal., 55, 424 – 428 (2011).
F. Monajjemzadeh, D. Hassanzadeh, H. Valizadeh, et al., Eur. J. Pharm. Biopharm., 73(3), 404 – 413 (2009).
E. Roumeli, A. Tsiapranta, E. Pavlidou, et al., J. Therm. Anal. Calorim., 111, 2109 – 2115 (2013).
S. Ini, Y. Shmueli, T. Koltai, and A. Gold, Duloxetine Hydrochloride Polymorphs, Patent WO2006081515 A2 (2006).
M. Bhadbhade, J. Hook, C. Marjo, et al, Acta Cryst., E65, o2294 (2009).
C. E. Marjo, M. Bhadbhade, J. M. Hook, and A. M. Rich, Mol. Pharm., 8, 2454 – 64 (2011).
M. A. Oliveira, Quim. Nova, 34, 1224 – 1230 (2011).
A. P. S. Matos, J. S. Costa, J. Boniatti, et al., J. Therm. Anal. Calorim., 127(2), 1675 – 1682 (2017).
A. Stimac, R. Jakse, N. Zajc, et al., Crystalline Forms of Duloxetine Hydrochloride and Processes for Their Preparation, Patent EP1820800 A1 (2006).
Acknowledgments
This study was funded in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES), Finance Code 001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Veiga, A., Stofella, N.C.F., Oliveira, L.J. et al. Thermal Analytical Approaches to Characterization and Compatibility Studies of Duloxetine Hydrochloride. Pharm Chem J 54, 659–666 (2020). https://doi.org/10.1007/s11094-020-02249-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-020-02249-0